Åsvold Bjørn O, Vatten Lars J, Bjøro Trine, Bauer Douglas C, Bremner Alexandra, Cappola Anne R, Ceresini Graziano, den Elzen Wendy P J, Ferrucci Luigi, Franco Oscar H, Franklyn Jayne A, Gussekloo Jacobijn, Iervasi Giorgio, Imaizumi Misa, Kearney Patricia M, Khaw Kay-Tee, Maciel Rui M B, Newman Anne B, Peeters Robin P, Psaty Bruce M, Razvi Salman, Sgarbi José A, Stott David J, Trompet Stella, Vanderpump Mark P J, Völzke Henry, Walsh John P, Westendorp Rudi G J, Rodondi Nicolas
Department of Public Health, Norwegian University of Science and Technology, Trondheim2Department of Endocrinology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Department of Public Health, Norwegian University of Science and Technology, Trondheim3Department of Epidemiology, Harvard School of Public Health, Harvard University, Boston, Massachusetts.
JAMA Intern Med. 2015 Jun;175(6):1037-47. doi: 10.1001/jamainternmed.2015.0930.
Some experts suggest that serum thyrotropin levels in the upper part of the current reference range should be considered abnormal, an approach that would reclassify many individuals as having mild hypothyroidism. Health hazards associated with such thyrotropin levels are poorly documented, but conflicting evidence suggests that thyrotropin levels in the upper part of the reference range may be associated with an increased risk of coronary heart disease (CHD).
To assess the association between differences in thyroid function within the reference range and CHD risk.
DESIGN, SETTING, AND PARTICIPANTS: Individual participant data analysis of 14 cohorts with baseline examinations between July 1972 and April 2002 and with median follow-up ranging from 3.3 to 20.0 years. Participants included 55,412 individuals with serum thyrotropin levels of 0.45 to 4.49 mIU/L and no previously known thyroid or cardiovascular disease at baseline.
Thyroid function as expressed by serum thyrotropin levels at baseline.
Hazard ratios (HRs) of CHD mortality and CHD events according to thyrotropin levels after adjustment for age, sex, and smoking status.
Among 55,412 individuals, 1813 people (3.3%) died of CHD during 643,183 person-years of follow-up. In 10 cohorts with information on both nonfatal and fatal CHD events, 4666 of 48,875 individuals (9.5%) experienced a first-time CHD event during 533,408 person-years of follow-up. For each 1-mIU/L higher thyrotropin level, the HR was 0.97 (95% CI, 0.90-1.04) for CHD mortality and 1.00 (95% CI, 0.97-1.03) for a first-time CHD event. Similarly, in analyses by categories of thyrotropin, the HRs of CHD mortality (0.94 [95% CI, 0.74-1.20]) and CHD events (0.97 [95% CI, 0.83-1.13]) were similar among participants with the highest (3.50-4.49 mIU/L) compared with the lowest (0.45-1.49 mIU/L) thyrotropin levels. Subgroup analyses by sex and age group yielded similar results.
Thyrotropin levels within the reference range are not associated with risk of CHD events or CHD mortality. This finding suggests that differences in thyroid function within the population reference range do not influence the risk of CHD. Increased CHD risk does not appear to be a reason for lowering the upper thyrotropin reference limit.
一些专家认为,当前参考范围内较高的血清促甲状腺激素水平应被视为异常,这种方法会将许多人重新归类为患有轻度甲状腺功能减退症。与这种促甲状腺激素水平相关的健康危害记录不足,但相互矛盾的证据表明,参考范围内较高的促甲状腺激素水平可能与冠心病(CHD)风险增加有关。
评估参考范围内甲状腺功能差异与冠心病风险之间的关联。
设计、设置和参与者:对14个队列进行个体参与者数据分析,这些队列在1972年7月至2002年4月期间进行了基线检查,中位随访时间为3.3至20.0年。参与者包括55412名血清促甲状腺激素水平为0.45至4.49 mIU/L且基线时无已知甲状腺或心血管疾病的个体。
以基线时血清促甲状腺激素水平表示的甲状腺功能。
在调整年龄、性别和吸烟状态后,根据促甲状腺激素水平得出的冠心病死亡率和冠心病事件的风险比(HRs)。
在55412名个体中,1813人(3.3%)在643183人年的随访期间死于冠心病。在10个同时有非致命和致命冠心病事件信息的队列中,48875名个体中的4666人(9.5%)在533408人年的随访期间经历了首次冠心病事件。促甲状腺激素水平每升高1 mIU/L,冠心病死亡率的HR为0.97(95%CI,0.90 - 1.04),首次冠心病事件的HR为1.00(95%CI,0.97 - 1.03)。同样,在按促甲状腺激素类别进行的分析中,促甲状腺激素水平最高(3.50 - 4.49 mIU/L)的参与者与最低(0.45 - 1.49 mIU/L)的参与者相比,冠心病死亡率(0.94 [95%CI,0.74 - 1.20])和冠心病事件(0.97 [95%CI,0.83 - 1.13])的HR相似。按性别和年龄组进行的亚组分析得出了类似的结果。
参考范围内的促甲状腺激素水平与冠心病事件风险或冠心病死亡率无关。这一发现表明,人群参考范围内的甲状腺功能差异不会影响冠心病风险。冠心病风险增加似乎不是降低促甲状腺激素参考上限的理由。